Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11732285 | 0.89 | L3MBTL1 (0.55) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL6527669 | 0.87 | ALDH1A1 (0.69) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL9873754 | 0.84 | KDM4E (0.62) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL26031862 | 0.84 | KMT2A (0.62) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL27784285 | 0.84 | KMT2A (0.63) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL23216981 | 0.82 | KDM4E (0.56) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL1923200 | 0.82 | KDM4E (0.59) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL27913159 | 0.82 | KMT2A (0.59) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL1666929 | 0.81 | CA12 (0.49) | KDM4EKMT2AMEN1LMNACA12 | |
| SCHEMBL15328698 | 0.81 | CA12 (0.52) | KDM4EKMT2AMEN1LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119770481-B | NR4A1 transcriptional activity inhibitor and application thereof | 浙江省肿瘤医院 | 2025-06-13 | — | — | CN | claimed |
| CN-106307378-A | Soup cooking base flavoring and preparation method thereof | 黔西南州万家绿宇康源保健品开发有限公司 | 2017-01-11 | — | — | CN | disclosed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | KDM4E 3504/4885KMT2A 2842/4885MEN1 4653/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | KDM4E 3504/4885KMT2A 2842/4885MEN1 4653/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | KDM4E 2334/4885KMT2A 3207/4885MEN1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.